Clinical trials
Urothelial Bladder Cancer clinical trials
Below are recruiting urothelial bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 213 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07614594Recruiting
Urine Test to Detect Bladder and Kidney Cancer
This study tests whether a simple urine test can accurately identify cancer in the bladder, ureters (tubes between kidneys and bladder), or renal pelvis (part of the kidney). You would provide urine samples before your planned surgery, and researchers will compare the urine test results to your actual tissue diagnosis after surgery.
Zhengzhou, HenanAges 18 years+ - NCT06781879RecruitingPhase 4
Comparing bladder medication vs surgery for returning low-grade bladder cancer
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
AalborgAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Tucson, ArizonaAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Birmingham, AlabamaAges 18 years+ - NCT04947059RecruitingPhase 3
Stop bladder cancer coming back with medicine after bladder surgery
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
Larissa, Larissa/ThessalyAges 18–100 - NCT05002556Recruiting
Bladder cancer follow-up registry for adults in France
This trial is a real-world registry that collects information during follow-up for certain early-stage bladder cancer. It may help doctors understand how urinary test results relate to recurrence and guide monitoring over time.
Aix-en-ProvenceAges 18 years+ - NCT05327647RecruitingPhase 2
Bicalutamide with BCG for bladder cancer after BCG treatment
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
London, OntarioAges 18 years+ - NCT06245603Recruiting
Testing Hydeal Cyst with standard treatment for bladder cancer
This study tests a bladder instillation called Hydeal Cyst, given alongside standard BCG or MMC therapy, to see if it helps reduce side effects or improve outcomes for people with non-muscle invasive bladder cancer.
BergamoAges 18 years+ - NCT06632964RecruitingPhase 1
Testing VT-101 for non-muscle invasive bladder cancer
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
Xuzhou, JiangsuAges 18–75 - NCT05951179RecruitingPhase 2
Bladder instillation study for high-grade non–muscle-invasive cancer
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
Homewood, AlabamaAges 18 years+ - NCT06983210RecruitingPhase 2
Combination treatment for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder or urinary tract cancer that has not been treated before. The goal is to see if adding AM80 to standard chemotherapy and immunotherapy works better.
Nagoya, Aichi-kenAges 18–79 - NCT03945162RecruitingPhase 2
Bladder cancer trial using light therapy in the bladder
This Phase 2 study tests a treatment called photodynamic therapy (PDT) placed directly into the bladder. It may help people whose non–muscle-invasive bladder cancer did not respond to BCG treatment or could not tolerate it.
Chicago, IllinoisAges 18 years+ - NCT04588168Recruiting
MRI helps guide bladder cancer treatment planning
This trial uses special MRI scans to help doctors choose precise treatment for bladder cancer before and/or around surgery. It may help tailor therapy more accurately while you receive standard bladder cancer care.
Nanjing, JiangsuAges 18 years+ - NCT06269536Recruiting
Stress reduction program for muscle-invasive bladder cancer
This trial tests a stress-reducing program for people with muscle-invasive bladder cancer. It aims to see if lowering stress can help with treatment outcomes and quality of life.
BratislavaAges 18 years+ - NCT06892860RecruitingPhase 2
Comparing shorter vs longer chemo before immunotherapy for bladder cancer
This trial is testing whether 3 cycles of chemotherapy are as effective as 6 cycles before starting maintenance immunotherapy (avelumab) for people with advanced bladder cancer. The goal is to see if a shorter chemo course can reduce side effects while still controlling the cancer.
ParisAges 18 years+ - NCT04442724Recruiting
MRI and bladder marker planning to guide bladder chemoradiation
This trial uses special MRI scans and tiny markers placed in the bladder to better plan bladder chemoradiation. The goal is to help target treatment more accurately and improve how well it can be delivered.
Los Angeles, CaliforniaAges 18 years+ - NCT06241755RecruitingPhase 3
BCG to prevent bladder cancer return after surgery
This study tests if BCG therapy can prevent bladder cancer from coming back after surgery. It's for people with early-stage bladder cancer that hasn't spread into the muscle layer.
Guangzhou, GuangdongAges 18–75 - NCT06525571RecruitingPhase 3
Blue light surgery for high-risk bladder cancer
This trial tests if using blue light during surgery helps remove all cancer in people with high-risk non-muscle invasive bladder cancer. It may lower the chance of the cancer coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Santa Rosa, CaliforniaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT04865939RecruitingPhase 3
Gemcitabine treatment compared with bladder wash in UTUC surgery
This Phase 3 trial studies whether using gemcitabine (a chemotherapy medicine) in the urinary tract better prevents cancer from coming back than using a simple water wash. It involves people with upper tract urothelial carcinoma who are having curative surgery to remove the affected ureter or kidney tube.
Dallas, TexasAges 18–90 - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Urothelial Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urothelial bladder cancer?
- Yes. Clin2 currently lists 213 recruiting urothelial bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urothelial bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urothelial bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.